NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $12.60 -0.36 (-2.78%) Closing price 04:00 PM EasternExtended Trading$12.60 0.00 (-0.04%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Enanta Pharmaceuticals Stock (NASDAQ:ENTA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enanta Pharmaceuticals alerts:Sign Up Key Stats Today's Range$12.47▼$13.0350-Day Range$11.88▼$14.1552-Week Range$10.20▼$17.15Volume218,871 shsAverage Volume284,046 shsMarket Capitalization$366.91 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingModerate Buy Company Overview Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases. Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection. Enanta also discovered paritaprevir, another HCV antiviral used in earlier AbbVie combination regimens. These products have helped establish the company’s expertise in antiviral drug discovery, although commercialization and marketing activities are conducted primarily through partners. Founded in 1995 and headquartered in Watertown, Massachusetts, Enanta conducts research and clinical development activities through its U.S. operations and collaborations with pharmaceutical companies. The company is led by Jay R. Luly, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Enanta Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreENTA MarketRank™: Enanta Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 658th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEnanta Pharmaceuticals has a consensus price target of $19.00, representing about 50.8% upside from its current price of $12.60.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($2.36) to ($2.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.09% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 10.72, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 0.62%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.48% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTA Stock News HeadlinesWall Street Zen Upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) to "Hold"October 3 at 1:13 AM | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Has Average Target Price of $21.00 According to AnalystsSeptember 30, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 5 at 1:00 AM | Stansberry Research (Ad)Fortress Biotech (NASDAQ:FBIO) versus Enanta Pharmaceuticals (NASDAQ:ENTA) Head to Head AnalysisSeptember 29, 2026 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Earns Buy Rating from HC WainwrightSeptember 25, 2026 | americanbankingnews.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026August 10, 2026 | businesswire.comEnanta Faces Patent Setback in Paxlovid LitigationJune 23, 2026 | tipranks.comEnanta Pharmaceuticals Announces Public Stock OfferingApril 11, 2026 | msn.comSee More Headlines ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $15.77 at the beginning of the year. Since then, ENTA shares have decreased by 20.1% and is now trading at $12.60. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.16. The biotechnology company had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.84% and a negative net margin of 96.89%. When did Enanta Pharmaceuticals IPO? Enanta Pharmaceuticals (ENTA) raised $60 million in an initial public offering (IPO) on Thursday, March 21st 2013. The company issued 4,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG). Company Calendar Last Earnings8/10/2026Today10/05/2026Next Earnings (Estimated)11/16/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ENTA's financial health is in the Green zone, according to TradeSmith. ENTA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENTA CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees120Year Founded1995Price Target and Rating Average Price Target for Enanta Pharmaceuticals$19.00 High Price Target$20.00 Low Price Target$17.00 Potential Upside/Downside+50.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.89 million Net Margins-96.89% Pretax Margin-96.74% Return on Equity-61.84% Return on Assets-20.70% Debt Debt-to-Equity RatioN/A Current Ratio3.76 Quick Ratio3.76 Sales & Book Value Annual Sales$65.32 million Price / Sales5.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.03 per share Price / Book4.16Miscellaneous Outstanding Shares29,120,000Free Float25,781,000Market Cap$366.91 million OptionableOptionable Beta0.96 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ENTA) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
